Pamrevlumab
drug drugOn this page
Also known as FG-3019
Summary
Pamrevlumab (CHEMBL2109377) is a phase-3 clinical-stage antibody; indicated across 7 conditions including idiopathic pulmonary fibrosis and exocrine pancreatic carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 7 conditions
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109377 |
| Name | Pamrevlumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: FG-3019, Pamrevlumab, PAMREVLUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| idiopathic pulmonary fibrosis | 3 | MONDO:0800504 | EFO:0000768 |
| exocrine pancreatic carcinoma | 3 | MONDO:0005192 | EFO:0002618 |
| Duchenne muscular dystrophy | 3 | MONDO:0010679 | MONDO:0010679 |
| chronic hepatitis B virus infection | 2 | MONDO:0005366 | EFO:0004239 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| focal segmental glomerulosclerosis | 1 | MONDO:0100313 | EFO:0004236 |
| diabetes mellitus | 1 | MONDO:0005015 | EFO:0000400 |
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE3 | 5 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03941093 | PHASE3 | COMPLETED | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
| NCT03955146 | PHASE3 | TERMINATED | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| NCT04371666 | PHASE3 | TERMINATED | Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) |
| NCT04419558 | PHASE3 | TERMINATED | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| NCT04632940 | PHASE3 | TERMINATED | Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD |
| NCT05262309 | PHASE2/PHASE3 | COMPLETED | An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19 |
| NCT00913393 | PHASE2 | TERMINATED | Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy |
| NCT01217632 | PHASE2 | TERMINATED | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection |
| NCT01262001 | PHASE2 | COMPLETED | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis |
| NCT01890265 | PHASE2 | COMPLETED | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| NCT02210559 | PHASE1/PHASE2 | COMPLETED | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
| NCT02606136 | PHASE2 | TERMINATED | Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) |
| NCT04432298 | PHASE2 | TERMINATED | Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease |
| NCT00074698 | PHASE1 | COMPLETED | Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis |
| NCT00102297 | PHASE1 | COMPLETED | Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus |
| NCT00754143 | PHASE1 | COMPLETED | Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy |
| NCT00782561 | PHASE1 | TERMINATED | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) |
| NCT01181245 | PHASE1 | COMPLETED | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
| NCT02851381 | Not specified | WITHDRAWN | Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).